Press coverage about Acasti Pharma (NASDAQ:ACST) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acasti Pharma earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 44.9260029976127 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
ACST has been the subject of several recent analyst reports. ValuEngine raised shares of Acasti Pharma from a “sell” rating to a “hold” rating in a research note on Monday, November 20th. Benchmark initiated coverage on shares of Acasti Pharma in a research note on Friday, January 5th. They set a “buy” rating and a $7.00 price objective for the company.
Acasti Pharma (NASDAQ ACST) opened at $0.96 on Friday. Acasti Pharma has a one year low of $0.84 and a one year high of $3.36. The company has a market cap of $14.02, a price-to-earnings ratio of -1.22 and a beta of 1.49.
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.